Acción 300683 WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Wuhan Hiteck Biological Pharma Co.,Ltd

Acciones

300683

CNE1000034C5

Precio de cierre Shenzhen S.E.
Otros sitios de cotización
 00:00:00 26/04/2024 		Varia. Cinco días. Varia. 1 de enero.
23,82 CNY +1,49 % Gráfico intradía de Wuhan Hiteck Biological Pharma Co.,Ltd +9,42 % -34,03 %
21/04 Wuhan Hiteck Biological Pharma Co.,Ltd informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
2023 Wuhan Hiteck Biological Pharma Co.,Ltd informa de los resultados de los nueve meses finalizados el 30 de septiembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
Hiteck Biological Pharma Gets Nod to Trial Eye Drops
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it has received CNY 294.999985 million in funding from Nuode Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Shanghai Boshen Investment Center (Limited Partnership), Shenzhen Qianhai Eagle Fund Management Co., Ltd., UBS Group AG, Guodu Venture Capital Co., Ltd., and other investors
Hiteck Biological Pharma Gets Regulatory Consent for Share Sale
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it expects to receive CNY 300 million in funding
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
Wuhan Hiteck Biological Pharma Co.,Ltd Approves Board Appointments
Wuhan Hiteck Biological Pharma Co.,Ltd agreed to acquire additional 6.9416% stake in Beijing Shadong Biotechnology Co., Ltd. from Beijing Zhongguancun VC Development Co., Ltd.
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
Wuhan Hiteck Biological Pharma : Bio-Pharma Nets $91 Million From Private Placement
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
Wuhan Hiteck Biological Pharma Co., Ltd. announced that it has received CNY 599.972 million in funding from a group of investors
Xiweiai Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Wuhan Hiteck Biological Pharma Co.,Ltd
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 300683
  4. Noticias Wuhan Hiteck Biological Pharma Co.,Ltd
  5. Otros idiomas